Entrada Announces Positive Phase 1/2 DMD Data
Entrada Therapeutics announces Cohort 1 of the ELEVATE-45-201 study met primary objectives with favorable safety and a statistically significant mean increase in dystrophin production.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed